Sign In
Buy KVUE
$16.83
-0.490 (-2.83%)
At Close: Jun 03, 2026
3 Great Value Stocks That Could Crush the S&P 500 This Year
06:05am, Sunday, 02'nd Mar 2025
With the overall market looking expensive, it can be prudent for investors in search of new stocks to add to their portfolios to dig into companies that, for whatever reason, are trading at discounts.
3 Top High-Yield Dividend Stocks I Just Bought in My Retirement Account
05:03am, Saturday, 01'st Mar 2025
I'm filling my retirement account with dividend stocks. While I like to see the passive income flow into my portfolio, that's not the main factor.
Buy 3 "Safer" Dividend Kings Of 24 Out Of 52 For February
10:08am, Thursday, 27'th Feb 2025
Seven of the top-ten Dividend Kings by yield offer annual dividends from a $1K investment exceeding their single share prices, making them attractive buys. Six Dividend Kings, including Altria Group a
Buy This Ultra-Safe High-Yield Dividend King Stock for Reliable Passive Income
03:25am, Friday, 21'st Feb 2025
Kenvue (KVUE 0.54%) stock is down since completing its spin-off from Johnson & Johnson (JNJ 1.13%) in August 2023. But with more than a year of results now in the books, investors have had time to acc
Looming Challenges, But Kenvue Could Become A Compelling Dividend Growth Stock Beyond 2025
02:00pm, Monday, 17'th Feb 2025
Kenvue, spun off from Johnson & Johnson, shows potential as a solid dividend stock post-2025 despite current economic challenges and recent earnings misses. The company boasts strong brands like Tyl
Buy 2 February S&P 500 Dividend Aristocrats Out Of 38 'Safer'
09:30am, Friday, 14'th Feb 2025
Five of the ten lowest-priced Dividend Aristocrats - Franklin Resources, Realty Income, Amcor, Hormel, and Kenvue - are recommended buys, offering dividends exceeding their single share prices. Analys
Kenvue to Webcast Presentation at the Consumer Analyst Group of New York Conference
06:45am, Thursday, 13'th Feb 2025
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced Thibaut Mongon, Chief Executive Officer, Paul Ruh, Chief Financial Officer, and Charmaine England, Chief Growth Officer, will
Kenvue: An Intriguing Turnaround
12:03am, Monday, 10'th Feb 2025
Kenvue's stock has underperformed since its IPO, with disappointing guidance cuts for 2023 and 2024, and minimal growth projected for 2025. Despite recent struggles, Kenvue's strong brand portfolio, i
Kenvue Is A Mediocre Candidate
07:44am, Saturday, 08'th Feb 2025
Kenvue, the world's largest pure-play consumer health company, has a market cap of $37.96 billion but struggles with profitability despite decent growth. Management's cost-cutting initiatives show pro
Kenvue, Inc. (KVUE) Q4 2024 Earnings Call Transcript
02:41pm, Thursday, 06'th Feb 2025
Kenvue, Inc. (NYSE:KVUE ) Q4 2024 Earnings Conference Call February 6, 2025 8:00 AM ET Company Participants Thibaut Mongon - CEO Paul Ruh - CFO Sofya Tsinis - Head, IR Conference Call Participants Fil
Kenvue (KVUE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Thursday, 06'th Feb 2025
The headline numbers for Kenvue (KVUE) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Kenvue's Q4 Sales Miss, Margins Improve
09:24am, Thursday, 06'th Feb 2025
Consumer healthcare products specialist Kenvue (KVUE -0.34%) reported mixed fourth-quarter and full-year earnings on Thursday, Feb. 6. Adjusted earnings per share (EPS) of $0.26 aligned with the marke
Kenvue (KVUE) Q4 Earnings Meet Estimates
08:56am, Thursday, 06'th Feb 2025
Kenvue (KVUE) came out with quarterly earnings of $0.26 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.31 per share a year ago.
Kenvue sees 2025 profit below estimates as strong dollar, weak cough product sales hit
06:49am, Thursday, 06'th Feb 2025
Consumer health company Kenvue forecast 2025 adjusted profit below Wall Street estimates on Thursday, hit by a stronger dollar and weak demand for its cough and cold products that include Tylenol and
Kenvue Reports Full Year and Fourth Quarter 2024 Results
06:45am, Thursday, 06'th Feb 2025
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), today announced financial results for the full year and fiscal fourth quarter ended December 29, 2024. “We delivered on our 2024 profit com
